Anti-EFR3B/ KIAA0953 monoclonal antibody

Anti-EFR3B/ KIAA0953 antibody for FACS & in-vivo assay

Target products collectionGo to EFR3B/EFR3B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2095-Ab-1/ GM-Tg-hg-MP2095-Ab-2Anti-Human EFR3B monoclonal antibodyHuman
GM-Tg-rg-MP2095-Ab-1/ GM-Tg-rg-MP2095-Ab-2Anti-Rat EFR3B monoclonal antibodyRat
GM-Tg-mg-MP2095-Ab-1/ GM-Tg-mg-MP2095-Ab-2Anti-Mouse EFR3B monoclonal antibodyMouse
GM-Tg-cynog-MP2095-Ab-1/ GM-Tg-cynog-MP2095-Ab-2Anti-Cynomolgus/ Rhesus macaque EFR3B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2095-Ab-1/ GM-Tg-felg-MP2095-Ab-2Anti-Feline EFR3B monoclonal antibodyFeline
GM-Tg-cang-MP2095-Ab-1/ GM-Tg-cang-MP2095-Ab-2Anti-Canine EFR3B monoclonal antibodyCanine
GM-Tg-bovg-MP2095-Ab-1/ GM-Tg-bovg-MP2095-Ab-2Anti-Bovine EFR3B monoclonal antibodyBovine
GM-Tg-equg-MP2095-Ab-1/ GM-Tg-equg-MP2095-Ab-2Anti-Equine EFR3B monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2095-Ab-1/ GM-Tg-hg-MP2095-Ab-2; GM-Tg-rg-MP2095-Ab-1/ GM-Tg-rg-MP2095-Ab-2;
GM-Tg-mg-MP2095-Ab-1/ GM-Tg-mg-MP2095-Ab-2; GM-Tg-cynog-MP2095-Ab-1/ GM-Tg-cynog-MP2095-Ab-2;
GM-Tg-felg-MP2095-Ab-1/ GM-Tg-felg-MP2095-Ab-2; GM-Tg-cang-MP2095-Ab-1/ GM-Tg-cang-MP2095-Ab-2;
GM-Tg-bovg-MP2095-Ab-1/ GM-Tg-bovg-MP2095-Ab-2; GM-Tg-equg-MP2095-Ab-1/ GM-Tg-equg-MP2095-Ab-2
Products NameAnti-EFR3B monoclonal antibody
Formatmab
Target NameEFR3B
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-EFR3B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species EFR3B/ KIAA0953 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2095
    Target NameEFR3B
    Gene ID22979,668212,313928,693990,475686,101087472,517590,100071529
    Gene Symbol and SynonymsC030014M07Rik,EFR3B,KIAA0953,mKIAA0953,RGD1310845
    Uniprot AccessionQ9Y2G0
    Uniprot Entry NameEFR3B_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000084710
    Target ClassificationN/A

    The target: EFR3B, gene name: EFR3B, also named as KIAA0953. Involved in phosphatidylinositol phosphate biosynthetic process and protein localization to plasma membrane. Located in actin cytoskeleton; cytosol; and plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.